TY - JOUR
T1 - Resistin family proteins in pulmonary diseases
AU - Lin, Qing
AU - Johns, Roger A.
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH) Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage II (CADET II) Grant 5UH2HL123827-02 and NIH National Heart, Lung, and Blood Institute Grant 1R01HL138497-01A1 (to R.A.J.).
Publisher Copyright:
Copyright © 2020 the American Physiological Society
PY - 2020/9
Y1 - 2020/9
N2 - The family of resistin-like molecules (RELMs) consists of four members in rodents (RELMα/FIZZ1/HIMF, RELMβ/FIZZ2, Resistin/FIZZ3, and RELMγ/FIZZ4) and two members in humans (Resistin and RELMβ), all of which exhibit inflammation-regulating, chemokine, and growth factor properties. The importance of these cytokines in many aspects of physiology and pathophysiology, especially in cardiothoracic diseases, is rapidly evolving in the literature. In this review article, we attempt to summarize the contribution of RELM signaling to the initiation and progression of lung diseases, such as pulmonary hypertension, asthma/allergic airway inflammation, chronic obstructive pulmonary disease, fibrosis, cancers, infection, and other acute lung injuries. The potential of RELMs to be used as biomarkers or risk predictors of these diseases also will be discussed. Better understanding of RELM signaling in the pathogenesis of pulmonary diseases may offer novel targets or approaches for the development of therapeutics to treat or prevent a variety of inflammation, tissue remodeling, and fibrosis-related disorders in respiratory, cardiovascular, and other systems.
AB - The family of resistin-like molecules (RELMs) consists of four members in rodents (RELMα/FIZZ1/HIMF, RELMβ/FIZZ2, Resistin/FIZZ3, and RELMγ/FIZZ4) and two members in humans (Resistin and RELMβ), all of which exhibit inflammation-regulating, chemokine, and growth factor properties. The importance of these cytokines in many aspects of physiology and pathophysiology, especially in cardiothoracic diseases, is rapidly evolving in the literature. In this review article, we attempt to summarize the contribution of RELM signaling to the initiation and progression of lung diseases, such as pulmonary hypertension, asthma/allergic airway inflammation, chronic obstructive pulmonary disease, fibrosis, cancers, infection, and other acute lung injuries. The potential of RELMs to be used as biomarkers or risk predictors of these diseases also will be discussed. Better understanding of RELM signaling in the pathogenesis of pulmonary diseases may offer novel targets or approaches for the development of therapeutics to treat or prevent a variety of inflammation, tissue remodeling, and fibrosis-related disorders in respiratory, cardiovascular, and other systems.
KW - FIZZ1
KW - HIMF
KW - Inflammation
KW - Lung
KW - RELMs
UR - http://www.scopus.com/inward/record.url?scp=85089787840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089787840&partnerID=8YFLogxK
U2 - 10.1152/ajplung.00040.2020
DO - 10.1152/ajplung.00040.2020
M3 - Review article
C2 - 32692581
AN - SCOPUS:85089787840
VL - 319
SP - L422-L434
JO - American Journal of Physiology
JF - American Journal of Physiology
SN - 1040-0605
IS - 3
ER -